Ozempic vs Wegovy: Same Drug, Different Purpose

If you've been researching weight loss medications, you've probably seen both Ozempic and Wegovy mentioned — often in confusing, contradictory ways. Some sources say they're the same drug. Others claim one is better than the other. The reality is nuanced, and understanding the differences could save you thousands of dollars and months of frustration.

Both medications are manufactured by Novo Nordisk and contain the same active ingredient: semaglutide, a GLP-1 receptor agonist. But they differ in important ways — dose, FDA approval, insurance coverage, and clinical evidence. This guide breaks down everything based on published clinical trial data.

Key differences at a glance

Same ingredient, different doses

Semaglutide works by mimicking GLP-1, a natural hormone that regulates appetite and blood sugar. When you inject semaglutide, it signals your brain that you're full, slows stomach emptying, and reduces cravings. The result: you eat less without feeling like you're starving.

The critical difference is the maximum dose. Ozempic tops out at 2.0 mg per week, while Wegovy goes up to 2.4 mg. That extra 0.4 mg might not sound like much, but in clinical trials it translated to meaningfully more weight loss. Wegovy also has a more gradual dose-escalation schedule (five steps vs. four) specifically designed for weight management patients.

Weight loss: what the clinical trials show

The strongest evidence for semaglutide and weight loss comes from the STEP clinical trial program — a series of large, randomized controlled trials published in the New England Journal of Medicine.

STEP 1: The landmark Wegovy trial

The STEP 1 trial enrolled 1,961 adults with obesity or overweight and tested Wegovy (semaglutide 2.4 mg) against placebo for 68 weeks. The results were remarkable: participants on semaglutide lost an average of 14.9% of their body weight, compared to 2.4% on placebo. For a 220-pound person, that's roughly 33 pounds.

STEP 5: Sustained results over 2 years

Perhaps more importantly, the STEP 5 trial showed these results hold up over time. After 104 weeks (2 full years), participants on semaglutide 2.4 mg maintained a weight loss of 15.2%, with 77% achieving at least 5% reduction. This addressed one of the biggest concerns about weight loss drugs — whether the effects last.

How does Ozempic compare?

Ozempic's clinical trials (SUSTAIN program) focused primarily on blood sugar control in diabetes, not weight loss. However, significant weight reduction was observed as a secondary outcome. At the 1.0 mg dose, patients typically lost 4-6% of body weight. At the 2.0 mg dose (added later), weight loss was somewhat higher but still below what Wegovy achieves at 2.4 mg.

The bottom line: if weight loss is your primary goal, Wegovy's higher dose produces better results based on published evidence. If you have type 2 diabetes and want to manage both blood sugar and weight, Ozempic at 2.0 mg can help with both.

Side effects comparison

Because Ozempic and Wegovy contain the same active ingredient, their side effect profiles are nearly identical. The main difference is that higher doses tend to produce more gastrointestinal side effects, so Wegovy's 2.4 mg may cause slightly more issues than Ozempic's lower doses.

Based on data from the STEP 1 trial, the most common side effects at the 2.4 mg dose were:

• Nausea — reported by 44% of patients (vs. 18% on placebo). Usually worst during dose escalation and improves over time.
• Diarrhea — 30% of patients. Typically mild and intermittent.
• Vomiting — 24% of patients. More common during dose increases.
• Constipation — 24% of patients.

Most gastrointestinal side effects were mild to moderate and tended to decrease after the first 2-3 months. Only about 7% of patients in the STEP 1 trial discontinued treatment due to side effects.

Both medications carry the same boxed warning about thyroid C-cell tumors (observed in animal studies) and warnings about pancreatitis, gallbladder problems, and kidney issues. For a detailed month-by-month breakdown, read our GLP-1 side effects guide.

Cost and insurance coverage

Without insurance, both medications are expensive — Ozempic runs approximately $900-1,000/month and Wegovy $1,300-1,350/month at retail prices. However, what you actually pay depends heavily on your insurance.

If you have type 2 diabetes

Ozempic is more likely to be covered because it's FDA-approved for diabetes management. Most commercial insurance plans and Medicare Part D cover Ozempic with varying copays ($25-150/month is typical).

If you want weight loss without diabetes

Wegovy coverage has expanded significantly in 2025-2026, but it's still inconsistent. Many employer-sponsored plans now cover it after the SELECT trial showed cardiovascular benefits. However, Medicare still does not cover weight loss medications, and Medicaid coverage varies by state.

For patients paying out of pocket, compounded semaglutide through telehealth providers offers a much more affordable option at $129-300/month.

Manufacturer savings programs

Novo Nordisk offers savings cards for both medications that can reduce your copay to as low as $0-25/month if you have commercial insurance. These programs don't apply to government insurance (Medicare, Medicaid, TRICARE).

Off-label Ozempic for weight loss

Many doctors prescribe Ozempic "off-label" for weight loss in patients who don't have diabetes. This is legal and common — physicians can prescribe any FDA-approved drug for any purpose they deem medically appropriate.

Why would a doctor prescribe Ozempic instead of Wegovy?

• Availability — Wegovy has faced intermittent supply shortages since its launch. Ozempic has been generally easier to obtain.
• Insurance workarounds — some patients find it easier to get Ozempic covered, especially if they have prediabetes or insulin resistance.
• Lower dose preference — some patients do well at 1.0 mg and don't need Wegovy's higher dose range.

However, there are downsides to off-label Ozempic use: insurance may deny the claim if the diagnosis code doesn't match, you can't access Wegovy's higher 2.4 mg dose, and the evidence base for weight management is stronger for Wegovy.

Which is right for you?

Choose Wegovy if:

• Weight loss is your primary goal
• You don't have type 2 diabetes
• Your insurance covers it, or you're willing to pay out of pocket
• You want the highest evidence-based dose (2.4 mg)

Choose Ozempic if:

• You have type 2 diabetes and want blood sugar + weight management
• Your insurance covers Ozempic but not Wegovy
• Wegovy is unavailable in your area
• You respond well to lower semaglutide doses

Consider compounded semaglutide if:

• You're paying out of pocket and cost is the primary factor
• You want an all-inclusive telehealth program ($129-300/month)
• You've confirmed the provider uses a licensed 503A or 503B pharmacy

For a full comparison of compounded options, see our cheapest GLP-1 online guide.

Frequently asked questions

Sources and clinical references